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Pharmaceutical formulation research has recently been focusing on delivery systems which provide long 
therapeutic effects and reduced side effects, and involving simplified production stages and facilitated 
application process. In situ forming microparticle (ISM) systems, one of the latest approach in this field, 
offer a new encapsulation technique and meet the objectives stated above. Factors such as the carrier 
used to form the multiparticles, amount and type of drug and the vehicle type can be taken as the main 
performance criteria for these systems. Ongoing studies have shown that this new multiparticulate drug 
delivery system is suitable for achieving new implant delivery system with low risk of dose-dumping, 
capable of being modulated to exhibit varying release patterns, reproducible, easily applicable and well-
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Various intramuscular or subcutaneous 
controlled drug delivery systems in the form 
of implants or microparticles have been 
developed based on biodegradable polymers. 
There are different techniques available to 
form drug–polymer composites as implants or 
microparticles [1-2]. Implants are generally 
formed by blending drug, polymer and 
additives followed by melt extrusion, melt 
compression or injection molding to obtain 
the desired implant size or shape [2]. 
Problems have occurred with these 
processes include elevated process 
temperature, poor content uniformity 
(especially with low-dose drugs) and often 
the requirement of surgical administration [1]. 
Additionally preparation of biodegradable 
implants and especially of microparticles is 
complicated and involves multiple-step 
processes and formulation parameters to be 
controlled, and this has also affect scale-up 
and cost [3].  
 
In order to avoid inconvenient surgical 
insertion of large implants, injectable 
biodegradable and biocompatible polymeric 
particles (microspheres, microcapsules, 
nanocapsules, nanospheres etc.) could be 
employed for controlled drug delivery [3]. 
Microparticles of size < 250 µm, ideally < 125 
µm, are suitable for this purpose [4]. 
Biodegradable polymers used for these 
systems are natural or synthetic in origin and 
are degraded in vivo by suitable 
biodegradation kinetics, either enzymatically 
or non-enzymatically or both, to produce 
biocompatible and toxicologically safe by-
products which are further eliminated by 
normal metabolic pathways. The polymers 
selected for these systems must also meet 
some other requirements such as drug 
compatibility, suitable mechanical properties 
and ease of processing [5-7].  
 
Approaches to prolonged therapeutic 
injectables were initially studied as 
formulations of viscous oils, which could 
decrease drug diffusion rate [8-10]. Latest 
studies in this field are focused on the 
development of liquid drug-polymer 
formulations, which form implants in situ upon 
injection and contact with body fluids as an 
alternative to solid implants [11-13]. These 
liquid drug-polymer formulations are prepared 
by dissolving thermoplastic aliphatic 
poly(esters) such as poly(lactide) (PLA) and 
especially poly(lactide-co-glycolide) (PLGA) 
in water-miscible solvents such as N-methyl-
2-pyrrolidone (NMP), dimethyl sulfoxide 
(DMSO), etc. Upon injection of drug-
containing polymer solution, the polymer 
solidifies at the site of injection and forms an 
implant. This technology has been 
investigated for the delivery of model 
proteins, LHRH-antagonists, narcotic 
antagonists, growth factors, anti-inflammatory 
agents, antibiotic, antiemetic, antiasthmatic, 
antipsychotic and anticancer drugs [12,14-
21].  
 
Drug release from these systems follows 
Higuchi square root of time relationship [22] 
with a high burst release in general [23-27]. 
Potential solvent toxicity and high viscosity of 
polymer solutions causing injection problems 
can possibly be occurred to these systems 
[11-17,25-27]. To overcome these problems 
a novel in situ forming microparticle system 
has been developed [28-29]. ISM systems 
are based on an emulsion of an internal drug-
containing polymer solution and a continuous 
oil or aqueous phase. After injection, the 
inner polymeric phase hardens upon contact 
with body fluids and thus forms in situ 
microparticles. ISM systems have 
significantly reduced initial burst release and 
viscosity (which is primarily controlled by the 
external phase). Thus, easier injectability and 
reduced pain has been achieved, compared 
to use of the polymer solutions (in situ 
implant systems). Additionally ISMs are 
multiparticulates, and thus minimize 
variations in implant morphology (after 
solidification) and provide more consistent 
and reproducible drug release profile [28-34].   
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METHODS OF PREPARATION OF 
ISM SYSTEMS 
 
ISM systems consist of an internal drug-
containing polymer solvent phase (polymer 
phase) that is dispersed into an external oil or 
water phase. Following injection of this 
dispersion, the inner polymer phase hardens 
upon contact with body fluids and forms in 
situ microparticles. The preparation process 
for ISM is simple, when compared with 
classical techniques for the preparation of 
various other microparticles such as solvent 
evaporation or phase separation methods 
[28-29,34].   
 
Preparation of oil-in-oil (O/O)–ISM system 
 
The O/O–ISM system comprises of polymer 
solution phase and external oil phase. 
Polymer solution phase can be prepared by 
dissolving a biodegradable polymer such as 
PLA or PLGA in a water-miscible, 
biocompatible solvent (this may also act as a 
plasticizer for the polymer) such as NMP, 2-
pyrrolidone, dimethyl sulphoxide (DMSO), 
triacetin and/or low molecular weight grade of 
polyethylene glycol {such as polyethylene 
glycol (PEG) 200 or 400}, which are able to 
form highly concentrated polymer solutions in 
combination with surfactants such as 
polyethylene glycol sorbitan monooleate 
(Tween 80) or polyoxyethylene–polyoxy-
propylene copolymer (Pluronic F 68). Peanut 
oil and sesame oil (oil for injection) can be 
used as a biocompatible external oil phase 
with surfactants such as sorbitan monooleate 
(Span 80) or triglyceride (Miglyol 812) 
with/without aluminum stearate or aluminum-
monostearate. Subsequently, accurately 
weighed internal and external phases (in 
different ratios) are loaded preferably into 
polypropylene syringes A and B, respectively. 
The two syringes are coupled with a 
connector and emulsification can be achieved 
by pushing the content of syringe A into 
syringe B to and fro for 50 mixing cycles. At 
the end of this, the contents are pushed into 
one syringe, the connector is removed and a 
needle is attached, and is ready for use [19-
20, 31-38].  
 
Preparation of oil in-water (O/W) –ISM 
system 
 
The O/W–ISM system is able to prepare 
similar with O/O–ISM system, except some 
differences in the following aspects. This 
system consists of an internal polymer 
solution phase in a hydrophobic solvent such 
as ethyl acetate and an external aqueous 
phase containing aqueous surfactant like 
Poloxamer 188 (Lutrol F 68). Emulsification 
of O/W–ISM can be achieved by 25 mixing 
cycles in a two-syringe system as described 
above for O/O-ISM system [30, 39].  
 
PREVIOUS STUDIES ON ISM 
SYSTEMS 
 
In vitro studies 
 
The ISM system described by Jain et al is a 
solution of PLGA, triacetin, a model protein 
cytochrome c, PEG 400 and Tween 80 (Oil 
Phase 1) which is added dropwise with 
continuous homogenization to Miglyol 812-
Span 80 solution (Oil Phase 2), thereby 
inducing phase separation (coacervation) of 
PLGA and forming drug containing PLGA 
microglobules dispersed in the continuous 
phase. This dispersion has a viscous 
consistency, but is sufficiently syringeable. 
When injected, it comes in contact with water 
from aqueous buffer or physiological fluid, 
thus microglobules harden to form 
cytochrome c entrapped solid matrix type 
microspheres which has released the drug in 
a controlled fashion [35, 40]. Figure 1 shows 
schematic representation of this microsphere 
formation process [35].  
 
Jain et al also investigated the effects of the 
following formulation variables on the release 
characteristics of ISMs: (i) concentrations of 
hydrophilic solvent (PEG 400), encapsulated 
drug and hydrophilic excipient (mannitol); and 
(ii) types of encapsulated drug, red dye 
(micromolecules), Cytochrome c and 
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myoglobin (macromolecules)] and vehicles. 
Moreover, effects of formulation properties, 
process, and storage conditions (15 days/48 
oC) on physical stability of encapsulated 
protein were evaluated. It was observed that 
in vitro drug release increased with decrease 
in PEG 400 concentration, and increase in 
drug and mannitol concentrations. 
 
 
Figure 1:  Schematic representation of in situ 
PLGA microsphere formation process [35]. 
 
Drug release decreased with increase in 
molecular weight of the encapsulated drug. 
Substitution of triacetin with triethyl citrate 
and Miglyol 812 with soybean oil resulted in 
variation in release pattern of drug. Soybean 
oil (mixed triglyceride of unsaturated and 
saturated fatty acids) which is relatively more 
hydrophobic than Miglyol 812 (mixed C8-C10 
triglyceride of saturated fatty acids) produced 
relatively more hydrophobic PLGA 
microglobule dispersion, and thereby delayed 
the dissolution of released myoglobin [35].  
 
The above novel microencapsulation process 
overcomes some of the disadvantages 
associated with other methods by (a) 
excluding the use of unacceptable organic 
solvents like dichloromethane or NMP and 
using acceptable vehicle mixture instead to 
prepare biodegradable PLGA microspheres, 
(b) forming drug containing PLGA 
microglobules (pre-microspheres or 
embryonic microspheres) which can be 
considered as precursors of the final 
microsphere product; these on coming into 
contact with water harden to form discreet 
PLGA microspheres which subsequently 
exhibit non-variable, predictable, and 
controlled drug release profile, and (c) 
precluding the need for reconstitution of 
PLGA microspheres before their 
administration [41-42]. Thus, this novel 
microencapsulation method can be viewed as 
a modified coacervation process, wherein 
drug containing microglobules are converted 
to microspheres in situ [40-43]. 
 
Luan and Bodmeier investigated the 
influence of PLGA type (molecular weight 
and end-group functionality) on leuprolide 
release from ISM systems which were based 
on an emulsion of PLGA solution in NMP 
dispersed in an oil phase (sesame oil 
containing 2 % Span 80 and 2.5 % aluminum 
stearate). The results of in vitro drug release 
were in contrast to those for microparticles 
prepared by classical solvent evaporation 
method. The use of lower molecular weight 
PLGA resulted in lower initial release from 
ISMs than when higher molecular weight 
PLGA was used. ISMs prepared with PLGA 
combinations showed a decrease in initial 
release when low-molecular-weight PLGA 
content was increased. Slow solvent diffusion 
from low-molecular-weight PLGA droplets 
into release medium led to a less porous 
structure of solidified microparticles, which 
explains the lower initial release. Moreover 
PLGA with free carboxylic acid end groups 
led to a lower drug release compared to 
PLGA with esterified end groups [32]. 
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The influence of various formulation and 
processing parameters on drug release from 
ISM systems has been investigated in 
another study by Luan and Bodmeier. The 
systems consisted of leuprolide acetate-
containing internal polymer phase {PLGA 
(RG 503H)/PLA (R 202H) and NMP} and 
external oil phase (peanut/sesame oil, Span 
80 and aluminum monostearate). In vitro 
solidification and dissolution studies releaved 
that in situ forming microparticles prepared by 
using PLGA were spherical and had a 
smooth surface but a porous inner structure 
as seen in Figure 2A. Drug release from 
these ISMs [31] was occurred in two phases 
with a high initial release followed by an 
almost constant and slower release, as 
shown in Figure 3A. Drug release profiles 
obtained from ISMs prepared by using PLA 
were almost monophasic (Figure 3B) 
compared to ISMs that contained PLGA 
(Figure 3A). In particular, ISMs with 10 % 
drug loading and 40 % polymer concentration 
showed lower initial and almost linear drug 
release from days 2 to 150, and also 
exhibited a smooth surface with a less porous 
inner structure, which explains the slower 
drug release compared to others, as shown 
in Figures 2B and 3B. In contrast to RG 
503H, R 202H led to a much lower initial 
leuprolide release {Figs 3A and 3B); this 
could possibly be explained by the higher 
carboxylic acid content of lower molecular 
weight PLA (R 202H acidic number is 10 mg 
KOH/g versus 4 mg KOH/g for RG 503H)}. In 
both systems, leuprolide acetate and PLGA 
or PLA were dissolved in polar solvent NMP. 
Therefore existence of ionic interactions 
between polymer and drug was also possible 
and a stronger interaction in the presence of 
R 202H could impede drug loss from polymer 
solution and thus lead to a lower initial 
release [31].  
 
Kranz and Bodmeier investigated in vitro drug 
(diltiazem hydrochloride and buserelin 
acetate) release from ISM systems (PLA or 
PLGA in 2-pyrrolidone, NMP or DMSO  
dispersed into peanut oil phase) as a function 
of type of solvent and polymer, concentration 
of polymer and ratio of internal polymer 




Figure 2:  Scanning electron micrographs of ISMs 
(A) prepared with 30 % w/w RG 503H and 5 % 
w/w drug loading and (B) prepared with 40 % w/w 
R 202H and 10 % w/w drug loading (2B) [31].  
 
According to the data obtained, initial drug 
release from ISM systems decreased with 
increasing polymer concentration and 
decreasing polymer phase:external oil phase 
ratio. Decrease in the release of the drug was 
in the rank order of DMSO > NMP > 2-
pyrrolidone, for the biocompatible solvent. In 
contrast to the release of low molecular 
weight diltiazem hydrochloride, peptide 
release (buserelin acetate) was strongly 
dependent on polymer degradation/erosion. 
The results confirmed that ISM system 
significantly reduced burst effect due to the 
presence of an external oil phase compared 
to in situ implant systems [33]. 
 
In another study by Kranz and Bodmeier [36], 
the effects of key formulation variables on the 
release of bupivacaine hydrochloride from 
ISM systems and in situ forming implants 
were investigated. The ISM systems were 
prepared as a combination of PLA–solvent 
phase dispersed into an external peanut oil 
phase. The solvent release from ISMs and in 
situ forming implants into phosphate buffer 
which influences polymer precipitation rate 
was investigated as a function of the type of  
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Figure 3:  (A) Influence of drug loading ( =10%;  
= 5%; ▲ = 2.5% )  on leuprolide release from 
ISMs containing %30 w/w RG 503H; and (B) 
Leuprolide release from ISMs at different drug 
loadings and polymer concentrations (x = 15% 
drug, 30% R 202H;  = 10% drug, 30% R 202; = 
10% drug, 40% R 202H; all % are given w/w) [31].     
 
solvent (NMP, DMSO and 2-pyrrolidone), 
polymer concentration and polymer:oil phase 
ratio. Upon contact with the release medium, 
solvent release into buffer medium from ISMs 
was significantly slower compared to in situ 
forming implant solutions due to the presence 
of an external oil phase. The solvent release 
of ISM systems into phosphate buffer 
decreased with increasing polymer 
concentration and decreasing polymer:oil 
phase ratio. The type of solvent used 
decreased solvent release rate in the rank 
order: DMSO > NMP >> 2-pyrrolidone. A 
slower solvent release into the aqueous 
medium resulted in less porous 
microparticles, thus explaining the reduced 
initial drug release from ISM systems 
compared to in situ forming implant solutions 
[36]. 
 
Incorporation of a model protein hen egg 
white lysozyme with ISM system was also 
investigated by Körber and Bodmeier. 
Ternary solvent blends of DMSO, ethyl 
acetate and water were used to adjust the 
protein solubility in order to facilitate the 
incorporation of either dispersed or dissolved 
protein into the polymer solution to achieve a 
good entrapment and to get a low initial 
release. The ISM systems consisted of 
lysozyme-containing polymer solutions (40 % 
PLGA-RG 502H) in sesame oil (external 
phase). The release of lysozyme from ISMs 
was only slightly affected by the investigated 
DMSO/ethyl acetate/water ratios (100/0/0, 
75/25/0 and 70.5/23.5/6) and was 
incomplete. This result could be attributed to 
the protein, which is located in the polymer 
rich phase following solidification of ISMs and 
adsorption of the positively charged lysozyme 
to the negatively charged PLGA [44]. 
 
Stability of ISM systems  
 
Some aspects of the stability of ISM systems 
have been investigated by researchers. Jain 
et al investigated the effect of myoglobin 
(macromolecules) on the release 
characteristics of ISMs and reported that the 
physical stability of myoglobin (helical 
structure) was unaffected by formulation, 
process, and storage conditions [35]. Kranz 
et al [37] also investigated the stability of ISM 
systems and showed that  the stability of the 
ISM increased by dissolving Pluronic F68 in 
the polymer phase while placing  aluminum 
monostearate in the oil phase of the system. 
  
The stability of PLGA and leuprolide acetate 
in in-situ forming systems, either ISMs or 
polymer solutions and lyophilized sponges, 
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was investigated by Dong et al. It was found 
that degradation of PLGA increased with 
increasing storage temperature and water 
content in biocompatible solvents. Faster 
degradation occurred in polar protic solvents 
(2-pyrrolidone, PEG 400, triethyl citrate) than 
in polar aprotic solvents (NMP, DMSO, 
triacetin, ethyl acetate). The presence of 
leuprolide acetate significantly accelerated 
the PLGA degradation, especially in solution 
state. PLGA was stable in oily (sesame oil, 
soybean oil, medium chain triglyceride) 
suspensions at 4 °C and degraded only 
slightly faster than solid powder at 25 °C. No 
interaction between oils and PLGA was 
observed as indicated by an unchanged Tg of 
approximately 47 °C. Finally, leuprolide 
acetate was chemically stable in sponges, 
oils and polymer solutions in suspension 
state, but unstable (aggregation) when 
dissolved in the polymer solutions and stored 
at 25 and 40 °C [45]. 
 
The stability of Montelukast and haloperidol 
ISM systems were studied by Ahmed et al 
[19,20] while meloxicam ISM system was 
studied by Ibrahim et al [46]. These studies 
indicate that the best temperature of storage 
was 4 ºC for both systems which retained 
their stability for more than 12 months at 4 
ºC. 
 
In vitro - in vivo studies  
 
The influence of various preparation and 
formulation parameters on in vitro and                  
in vivo release of bupivacaine hydrochloride 
from ISM systems, which were prepared by 
emulsifying drug-containing polymer solutions 
(PLGA in 2-pyrrolidone) into a peanut oil 
phase at a polymer to oil phase ratio of 1:1, 
0.5:1, 0.25:1 and 0.1:1, was investigated by 
Kranz et al [37]. Ready-to-inject formulations 
were prepared by probe sonication. 
Alternatively, emulsion formation prior to 
injection was carried out using two syringes 
filled with polymer phase in the first and 
peanut oil phase in the second container. In 
vitro drug release was highly influenced by 
the polymer to oil phase ratio and initial drug 
release was reduced with decreasing 
polymer phase/external oil phase ratio.  
 
A hot plate model has been used in order to 
quantify the pharmacodynamic effect of 
bupivacaine release from ISM systems in 
male Sprague–Dawley rats. ISM with a 
polymer/oil phase ratio of 0.25:1 and 0.5:1 
were selected for in vivo studies due to 
reduced initial in vitro release of drug. The in 
vivo drug release studies were in good 
agreement with in vitro drug release data. 
With ISM system, the analgesic effect of 
bupivacaine hydrochloride was prolonged 
when compared to the injection of a drug 
solution or drug-polymer solution [37]. 
 
Rungseevijitprapaa and Bodmeier [30] 
evaluated the forces required to inject 
biodegradable emulsions of the ISM systems 
via different sizes of syringe and needle into 
a newly developed chicken meat model using 
the compression mode of a texture analyzer 
(Figure 4). The injection forces obtained were 
finally correlated with the injectability of 
formulations into living rats. The results 
indicate that the flow of ISM formulations 
through the needle could be described by the 
well-known Poiseuille equation. The injection 
forces obtained were directly proportional to 




Figure 4:  Illustration of the setup for injection force 
measurement with chicken meat      model [30]. 
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and the second power of the syringe plunger 
radius, and inversely proportional to the 
fourth power of the needle radius. This test 
method could differentiate very well the 
required forces from various formulations and 
injection conditions as well as different 
injection sites (muscle, subcutaneous tissues 
or air). In comparison to polymer solutions 
that form implants in situ, the ISM systems 
were more easily injectable with smaller 
needle size, and thus it was expected to be 
less painful and give better patient 
compliance [30]. 
 
Ahmed et al [19] studied the controlled 
release of montelukast (MK) using in situ 
forming  implants and ISM systems. PLGA 
solutions in NMP, DMSO, ethyl acetate or 
triacetin were used as in situ forming implants 
while ISMs were prepared by mixing PLGA in 
NMP or DMSO and emulsified into peanut oil. 
In vitro dissolution studies showed that in 
comparison with implant system, the ISM 
system showed lower initial burst and slower 
release of MK. In vivo studies were 
performed on male Sprague Dawley rats 
followed by intramuscular injection of the 
formulations. The pharmacokinetic data 
obtained demonstrated that sustained levels 
of MK plasma concentration (range 2432 - 48 
ng/mL)  was achieved for > 17 days for the 
implant-treated group and > 28 days 
(concentration range: 1466 - 62 ng/mL) for 
ISM-treated group. Similar formulations of 
haloperidol with MK were also studied by 
Ahmed et al [20]. In vitro release profiles of 
haloperidol were similar for ISM systems and 
in situ forming implants. The pharmacokinetic 
data demonstrated the sustained level of 
haloperidol plasma concentration for > 20 
days (concentration range 60 - 8 ng/mL) in 
animals injected with implant formulation and 
> 30 days (concentration range: 44 - 6 
ng/mL) in ISM-treated group. The results 
obtained for MK and haloperidol were 
encouraging when used in ISM systems for 
controlled drug delivery [19,20].  
 
Ibrahim et al investigated the extended 
release of meloxicam from ISM systems by 
both in vitro and in vivo studies. ISM systems 
were prepared by emulsifying drug-containing 
polymer solutions (PLGA in NMP) into peanut 
oil. Three distinct phases of drug release; 
initial burst, constant release, and rapid 
release were noticed for in vitro dissolution 
studies. Pharmacokinetics study revealed low 
initial burst and sustained drug release for 21 
days. In vivo drug release was faster than in 
vitro release. The data obtained showed that 
injectable ISM formulations would be a viable 
approach for providing extended delivery of 
meloxicam with low initial burst and long 
shelf-life [46]. 
 
Myotoxicity studies on ISM systems  
 
The potential in vitro and in vivo myotoxicity 
of ISM and in situ implant systems was 
investigated by Kranz et al [34]. Acute 
myotoxicity was evaluated in vitro using 
isolated rodent skeletal muscle model by 
measuring the cumulative creatine kinase 
(CK) efflux. Following intramuscular injection 
(i.m.) to male Sprague Dawley rats, the area 
under plasma CK-curve was used to evaluate 
muscle damage for in vivo study. While PLA 
in 2-pyrrolidone dispersed into peanut oil 
phase was used as ISM system, in situ 
forming implants were prepared as PLA 
solutions in 2-pyrrolidone, NMP or DMSO. 
Phenytoin and normal saline served as 
positive and negative controls, respectively. 
PLA in different solvents (in situ forming 
implants) resulted in 14.4 – 24.3 times higher 
CK-values compared to normal saline, 
indicating a high myotoxic potential. With ISM 
system, the CK-release was significantly 
lower, decreased with lower polymer phase: 
oil phase ratio, and approached the values of 
normal saline at a ratio of 1:4. Bupivacaine 
HCl- and buserelin acetate- containing ISM 
systems gave significantly lower CK-levels 
compared to the corresponding drug 
formulation in normal saline. As a result, in 
vivo studies confirmed the in vitro data and 
showed the good muscle compatibility of the 
ISM systems [34]. 
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Rungseevijitprapa et al have studied the 
myotoxicity potential of solvents used for 
preparation of polymer solutions and O/W-
ISM systems. The acute myotoxicity was 
investigated using in vitro isolated rodent 
skeletal muscle model by measuring the 
cumulative CK efflux. Phenytoin and isotonic 
sodium chloride solution served as positive 
and negative controls, respectively. The 
results obtained from in vitro myotoxicity 
studies suggested that five partially water 
miscible solvents caused muscle damage in 
the following rank order: benzyl alcohol > 
triethyl citrate > triacetin > propylene 
carbonate > ethyl acetate. Microscopic 
pictures of O/W-ISM formulation with varying 
solvent systems for the polymer are 
presented in Figure 5. Myotoxicity of ethyl 
acetate was comparable to that of isotonic 
sodium chloride solution. Emulsions of 
undiluted solvents and an aqueous 0.5 % 
Pluronic F 68 solution (ratio 1:4) could 
dramatically reduce the myotoxicities to 24 – 
65 %. The myotoxicity of O/W-ISM system 
was less than those of the polymer solutions 
and undiluted solvents. The cumulative CK 
level obtained from muscle-treated O/W-ISM 
with phase ratio 1:4 was comparable to those 




Figure 5:  Photomicrograohs of O/W-ISM 
formulations comprising internal phase (40% 
PLGA 502H in solvent) and external phase (0.5% 
Lutrol F 68 with a phase ratio of 1:1); (A) 60% 
ethyl acetate; (B) 40% ethyl acetate/20% PEG 
400; (C) 30% ethyl acetate/30% PEG 400 and (D) 
20% ethyl acetate/40% PEG 400. Magnification 20 
x [39]. 
under CK plasma curve obtained following 
intramuscular injection of formulations to 
Sprague–Dawley rats was used to evaluate 
in vivo myotoxicity. In vivo results correlated 
well with in vitro data and confirmed the good 
muscle compatibility of O/W-ISM formulations 
[39]. 
 
Recent studies by a firm (Rovi) have enabled 
it to develop commercial formulations of “in 
situ microparticles” (ISM™) for new 
therapeutic applications. Extended release 
formulations based on ISM™ technology are 
currently being developed for psychiatric and 
oncologic drugs due to their industrial 
potential, as well as commercial and sanitary 
interest. In September 2010, the 
experimental stage has begun for the first 
Phase I trial of Risperidone-ISM™ on healthy 
volunteers, which is the first candidate for this 
drug delivery system. This first trial aims 
mainly to evaluate the pharmacokinetics and 
tolerability of a single intramuscular 
administration of Risperidone in an ISM™ 
formulation. This trial will serve not only to 
confirm the pharmacokinetic profile of this 
innovative depot formulation for the monthly 
administration of an approved anti-psychotic, 
but it will also serve as a proof of concept for 
validating ISM technology as a base platform 
for other developments. In this regard, other 
new formulations with ISM™, for monthly 
administration of another widely used anti-
psychotic, and for quarterly administration of 
an approved aromatase inhibitor that is 
currently used extensively in the treatment of 
hormone-dependent breast cancer, are 




In situ forming microparticle (ISM) systems 
offer a new encapsulation technique that 
provides prolonged release of drug along with 
much greater ease of preparation and 
administration than conventional micropar-
ticles and surgically implanted systems. ISMs 
are an attractive alternative to parenteral drug 
delivery, especially those prepared by 
existing complicated microencapsulation 
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methods. Moreover, recent developments in 
this field such as the first Phase I trial of 
Risperidone-ISM™ suggest there is a 
possibility for prolonged release of bioactive 
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